Somatropin
- Half-Life (t½)
- SC: 2.6h · IV: 12m
- Aliases
- rhGH, Recombinant human growth hormone, Genotropin, Humatrope, Norditropin, Omnitrope, Saizen, Zomacton
Pharmacological Mechanism
Recombinant human 22 kDa growth hormone (191 aa, two intrachain disulfides, identical to pituitary somatotropin). Activates GHR (JAK2/STAT5) on hepatocytes → hepatic IGF-1 → systemic mitogenic / anabolic effects; direct effects at adipocytes (lipolysis) and myocytes. Plasma t½ ~2.6 h after SC injection; IGF-1 rise persists ~24 h, sustaining once-daily dosing. Long-acting derivatives (somapacitan, lonapegsomatropin) shift dosing to weekly.
Half-Life & Elimination Curve (SC: 2.6h · IV: 12m)
Plasma (SC)t½ Decay (2.6h)
- 0×t½0h100% (1.7 µg/L)
- 1×t½2.6h50% (0.848 µg/L)
- 2×t½5.2h25% (0.424 µg/L)
- 3×t½7.8h12.5% (0.212 µg/L)
- 4×t½10.4h6.3% (0.106 µg/L)
- 5×t½13h3.1% (0.053 µg/L)
Dosing Guidelines
- Subcutaneous (SC): Typical 0.2 mg (Range: 0.15–0.3 mg)
- Intramuscular (IM): Typical 0.2 mg (Range: 0.15–0.3 mg)
Pharmacokinetic Parameters
- Subcutaneous (SC): Bioavailability (F): 75% · Volume of Distribution (Vd): 28 L · Absorption (ka): 0.2 h⁻¹ (t½ka ≈ 3.47h) [PMID 33864240]
- Intravenous (IV): Bioavailability (F): 100% · Volume of Distribution (Vd): 3.46 L · Absorption (ka): 60 h⁻¹ (t½ka ≈ 1m) [PMID 10487702]
Pathways It Modulates
Target Organ Systems
- Endocrine System
- digestive
References